TMC435 is a protease inhibitor jointly developed by Medivir (STO:MVIRB) and Tibotec to treat hepatitis C virus infections (HCV). TMC435 is currently being developed in three phase 2b clinical trials (C205, C206 and C215) in G1 treatment-naïve and in G1 patients that failed previous IFN-based treatment.
• C205 is a global phase 2b study initiated in May 2009 in approximately 400 genotype-1 treatment-naïve patients. It is a once daily treatment of TMC435 in doses of 75 mg and 150 mg given in addition to standard of care treatment, consisting of ribavirin and pegIFNalpha-2A.
• C206 is a global phase 2b study initiated in September 2009 in approximately 455 genotype-1 treatment-experienced patients. It is a once daily treatment of TMC435 in doses of 100 mg and 150 mg given in addition to standard of care treatment.
• C215 is a phase 2b study in Japan initiated in June 2009 in approximately 90 genotype-1 treatment-naïve patients. It is a once daily treatment of TMC435 in doses of 50 mg and 100 mg given in addition to standard of care treatment.
During the International Liver Congress™ four posters on TMC435 were presented. The abstract titles are:
1. Combination of TMC435 with two novel NS5B inhibitors increases anti HCV activity and results in a higher genetic barrier in vitro
2. Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of TMC435 in Treatment-naive Hepatitis C (HCV)-infected patients in the OPERA-1 STUDY
3. Evaluation of Metabolic Interactions for TMC435 via Cytochrome P450 (CYP) Enzymes in Healthy Volunteers
4. Mathematical analysis of clinical data suggests that HCV genotype 1 has a high cellular infection rate that is reduced by Pegylated-Interferon alfa-2a/Ribavirin‹
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.